Publications by authors named "E G Corona-Sanchez"
Autoantibodies in the pathogenesis of idiopathic inflammatory myopathies: Does the endoplasmic reticulum stress response have a role?
Front Immunol
October 2022
Idiopathic inflammatory myopathies (IIMs) are a group of rare, acquired autoimmune diseases characterized by profound muscle weakness and immune cell invasion into non-necrotic muscle. They are related to the presence of antibodies known as myositis-specific antibodies and myositis-associated antibodies, which are associated with various IIM phenotypes and the clinical prognosis. The possibility of the participation of other pathological mechanisms involved in the inflammatory response in IIM has been proposed.
View Article and Find Full Text PDFArticle Synopsis
- There is a high rate of treatment failure with leflunomide (LEF) in rheumatoid arthritis (RA) patients, prompting this study to assess the effectiveness of teriflunomide levels (A77 1726) in predicting disease activity outcomes.
- The study involved comparing RA patients with low disease activity (DAS28-ESR ≤ 3.2) against those with moderate/severe disease activity (DAS28-ESR > 3.2) after LEF treatment in a sample of 115 patients.
- Results indicated that higher A77 1726 levels correlated negatively with disease activity, enabling high sensitivity and specificity in identifying patients who achieved better outcomes, thus showcasing its potential as a useful biomarker
Background: Fracture risk assessment tool (FRAX) index was developed for estimating of the 10-year risk of major or hip osteoporotic fracture. To date, there is insufficient information regarding the correlation between FRAX and serum bone turnover markers (BTMs), such as soluble ligand of receptor activator of nuclear factor-B (sRANKL), osteoprotegerin (OPG), and other molecules related with secondary osteoporosis in rheumatoid arthritis (RA). Therefore, this study is aimed at assessing the correlation between the FRAX and serum levels of sRANKL, OPG, sRANKL/OPG ratio, Dickkopf-1 (DKK-1), and sclerostin (SOST) in RA.
View Article and Find Full Text PDFObjectives: The presence of myositis-specific antibodies (MSA), was recently reported in healthy individuals, cancer patients without myopathy and paraneoplastic rheumatic syndromes. We sought to analyze the frequency of MSA, myositis-associated antibodies (MAA) and autoantibodies related to systemic autoimmune rheumatic diseases (SARD) in breast cancer patients.
Methods: One hundred fifty-two breast cancer patients were enrolled in a cross-sectional study.